China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.
The approvals cover supplementary research.
Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, while
Candesartan cilexetil is indicated for hypertension.
Indonesia is looking to boost economic ties with Kazakhstan in a bid to broaden its access to Eurasian markets, The Jakarta Globe reported, citing Coordinating Economic Affairs Minister Airlangga Hartarto."With Kazakhstan's geographic position and regional connectivity, there are significant opportunities to strengthen trade, investment, and industrial partnerships between the two countries," Airlangga said, according to The Jakarta Post.Airlangga met Kazakhstan Prime Minister Olzhas Bektenov on his ongoing visit to Astana, where the latter expressed support for increased economic cooperation between the two nations, according to the report.The countries have pledged collaboration in various sectors, including energy, the digital economy, agriculture, manufacturing, food processing, tourism, and Islamic banking.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Pop Mart International's (HKG:9992) revenue jumped 75% to 80% year over year in the first quarter.The Chinese toy company said Tuesday in a Hong Kong bourse filing that sales from China, Asia Pacific, America and Europe all grew over the period, as did revenue from its offline and online channels.
Suven Life Sciences' (NSE:SUVEN, BOM:530239) global phase 3 study for Masupirdine in agitation associated with Alzheimer's dementia achieved 76% patient enrollment.The 375-patient study is being conducted across Europe and North America, according to a Tuesday filing on Indian bourses.Patient enrollment is expected to be complete by September 2026, with data readout targeted for April 2027.